Serif Biomedicines Raises $50 Million

Flagship Pioneering has launched Serif Biomedicines, a new biotech company focused on Modified DNA medicines.

The company is starting with an initial $50 million commitment after five years of platform development.

Serif Biomedicines aims to build a novel therapeutic platform that could broaden the drug-development pipeline.